Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Return on Equity (2021 - 2025)

Aligos Therapeutics' Return on Equity history spans 5 years, with the latest figure at 0.39% for Q4 2025.

  • For Q4 2025, Return on Equity rose 1204.0% year-over-year to 0.39%; the TTM value through Dec 2025 reached 0.39%, up 1204.0%, while the annual FY2025 figure was 1.97%, 219.0% up from the prior year.
  • Return on Equity reached 0.39% in Q4 2025 per ALGS's latest filing, up from 1.0% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.39% in Q4 2025 to a low of 12.42% in Q4 2024.
  • Average Return on Equity over 5 years is 1.65%, with a median of 1.0% recorded in 2025.
  • Peak YoY movement for Return on Equity: plummeted -1123bps in 2024, then skyrocketed 1204bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.64% in 2021, then plummeted by -33bps to 0.85% in 2022, then tumbled by -40bps to 1.19% in 2023, then tumbled by -941bps to 12.42% in 2024, then soared by 97bps to 0.39% in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Return on Equity are 0.39% (Q4 2025), 1.0% (Q3 2025), and 0.68% (Q2 2025).